Mark S Sundrud Ph.D.
- Mailing Address:
-
Scripps Way
Jupiter FL 33458
- 2021 Nature
- 2021 Nature communications
- 2020 Scientific reports
- 2020 The Journal of experimental medicine
- 2020 Frontiers in immunology
- 2020 Immunity
- 2020 Proceedings of the National Academy of Sciences of the United States of America
- 2019 Mucosal immunology
- 2019 Mucosal immunology
- 2018 The Journal of investigative dermatology
- 2018 Current opinion in gastroenterology
- 2017 Immunity
- 2016 PloS one
- 2016 Inflammatory bowel diseases
- 2015 Cancer research
- 2015 Immunology
- 2014 Immunotherapy
- 2014 Journal of immunology (Baltimore, Md. : 1950)
- 2014 Journal of immunology (Baltimore, Md. : 1950)
- 2014 The Journal of experimental medicine
- 2014 Journal of leukocyte biology
- 2014 Immunity
- 2014 Trends in pharmacological sciences
- 2013 Seminars in immunology
- 2013 Journal of immunology (Baltimore, Md. : 1950)
- 2012 Nature chemical biology
- 2011 The Journal of experimental medicine
- 2010 Proceedings of the National Academy of Sciences of the United States of America
- 2010 Current opinion in immunology
- 2009 PloS one
- 2009 Science (New York, N.Y.)
- 2008 Immunity
- 2008 Immunity
- 2007 Trends in immunology
- 2007 Immunology and cell biology
- 2007 Journal of immunology (Baltimore, Md. : 1950)
- 2007 Current opinion in immunology
- 2006 Journal of virology
- 2006 PloS one
- 2005 Blood
- 2004 PLoS biology
- 2004 Proceedings of the National Academy of Sciences of the United States of America
- 2003 Journal of immunology (Baltimore, Md. : 1950)
-
2005
Ph.D. in Microbiology and ImmunologyVanderbilt University Medical Center
-
2000
Bachelor's of Science in Biology and PsychologyConcordia College
Matthew Pipkin Ph.D.
- Mailing Address:
-
120 SCRIPPS WAY
JUPITER FL 33458
The overall focus of the Pipkin lab is to elucidate how chromatin structure and transcription controls the gene expression programs that establish and maintain the differentiated states of T cells. The lab specifically studies how naïve CD8 T cells differentiate into effector and memory cytotoxic T lymphocytes (CTL). CTL are killer lymphocytes that hold outstanding promise for controlling viral infections and cancer therapeutically, as they can be employed in adoptive immunotherapy and are the target of successful vaccination. The Pipkin lab has developed novel approaches to map the fundamental repeating structures of chromatin (nucleosomes) at unprecedented resolution, novel reporter genes to track cells in vivo that induce expression of Prf1, an essential gene that is required for the anti-tumor killing activity of CTL, and the only systems to conduct genome-scale pooled RNAi screens in T cells, in vivo, during the course of actual viral infections. Using these tools and approaches, the Pipkin lab is clarifying how transcription factors govern the specific organization of nucleosomes that enforces CTL differentiation, identifying the chromatin regulatory factors that maintain the differentiated state epigenetically, and demonstrating how these processes mediate durable immunity.
-
2005
Ph.D. in Microbiology and ImmunologyUniversity of Miami, School of Medicine
-
1998
Bachelor's of Science in Microbiology and ImmunologyUniversity of Miami
Michael Farzan Ph.D.
- Mailing Address:
-
120 SCRIPPS WAY
JUPITER FL 33458
-
Elected Fellow2019 · American Academy of Microbiology
-
NIDA Avant-Garde Award, "A safety switch for an effective HIV-1 vaccine"2017-2022 · —
-
NIAID MERIT Award, "Therapeutic uses of an enhanced form of CD4-Ig"2016-2021 · —
-
Founder2015-2022 · Emmune Inc.
-
Grand Challenges Award2015-2019 · Bill and Melinda Gates Foundation
-
Top NIAID Research Advances2015 · —
-
Chair, Florida Curriculum Committee2014-2019 · The Scripps Research Institute
-
Member2010-2015 · NIH Systems Biology Working Group (SBWG)
-
Steering Committee, Infectious Disease Initiative2009-2014 · Broad Institute
-
Member2009-2013 · NIH AIDS Molecular and Cellular Biology (AMCB) Study Section
-
Kavli Fellowship2008 · The Kavli Foundation and the National Academy of Sciences
-
Editorial Board2007-2022 · Journal of Virology
-
Section Editor for Viral Pathogenesis2007-2016 · PLoS Pathogens
-
Awarded2007-2012 · Burroughs Wellcome Fund Investigators in Pathogenesis Award
-
Awarded2004 · GlaxoSmithKline Drug Discovery and Developmental Research Award
-
Richard A. Smith Prize2000 · Dana-Farber Cancer Institute
Our laboratory focuses on entry processes of enveloped viruses and the various ways that the innate and adaptive immune responses inhibit these processes. We also apply our insights toward developing therapeutic strategies that enhance or supplement these immune responses. Our work can be divided into three categories: (1) biochemical studies of the HIV-1 entry process and its inhibition, (2) identification and characterization of obligate factors, including receptors, necessary for the entry of other enveloped viruses, and (3) identification and characterization of host restriction factors that inhibit early steps in the viral life cycle, in particular those of the IFITM family.
In addition to these scientific goals, we are developing a means of providing sustained, universal protection from HIV-1. Our most effective strategy uses adeno-associated virus (AAV) to express, eCD4-Ig, an exceptionally broad and potent HIV-1 entry inhibitor. We have shown that this strategy protects rhesus macaques from virus challenges greater than any human is likely to encounter, and thus it provides more effective protection than any conventional vaccine approach. To improve the safety of this approach, we are also developing regulatory switches that can dose or inactivate an AAV transgene.
- 2022 Science Advances
- 2022 Molecular Therapy
- 2022 SLAS discovery : advancing life sciences R & D
- 2022 Nature Reviews Molecular Cell Biology
- 2021 Pharmaceuticals (Basel, Switzerland)
- 2021 PloS one
- 2021 PLOS Pathogens
- 2021 PLOS Pathogens
- 2021 Science (New York, N.Y.)
- 2021 Biochemical and biophysical research communications
- 2021 Proceedings of the National Academy of Sciences of the United States of America
- 2021 Pharmaceuticals (Basel, Switzerland)
- 2021 Nature
- 2021 mBio
- 2021 Nature Structural & Molecular Biology
- 2021 medRxiv : the preprint server for health sciences
- 2021 Molecular Therapy – Nucleic Acids
- 2020 Nature
- 2020 bioRxiv : the preprint server for biology
- 2020 Biochemistry
- 2020 Nature Communications
- 2020 Journal of virology
- 2020 bioRxiv : the preprint server for biology
- 2020 SLAS discovery : advancing life sciences R & D
- 2020 Molecular therapy. Methods & clinical development
- 2020 bioRxiv : the preprint server for biology
- 2020 Immunity
- 2020 Nature Biotechnology
- 2020 mBio
- 2020 bioRxiv : the preprint server for biology
- 2019 mBio
- 2019 Journal of virology
- 2019 JCI insight
- 2019 Nature
- 2019 Science Translational Medicine
- 2019 Journal of virology
- 2019 Molecular therapy : the journal of the American Society of Gene Therapy
-
2018
Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence.Molecular therapy : the journal of the American Society of Gene Therapy
- 2018 PLOS Pathogens
- 2018 Journal of virology
- 2018 PloS one
- 2017 Journal of virology
- 2017 Current opinion in HIV and AIDS
- 2017 PLOS Pathogens
- 2017 Nature chemical biology
- 2016 Journal of virology
- 2016 Journal of virology
-
2016
Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cellseLife
- 2016
- 2016 Journal of virology
- 2016 Proceedings of the National Academy of Sciences of the United States of America
- 2015 Nature
- 2015 Journal of virology
- 2015 Neuron
- 2015 mBio
- 2015 The Journal of biological chemistry
- 2015 Proceedings of the National Academy of Sciences of the United States of America
- 2014 Journal of virology
- 2014 Annual review of virology
- 2014 PloS one
- 2014 PloS one
- 2014 Proceedings of the National Academy of Sciences of the United States of America
- 2013 PLoS pathogens
- 2013 Cell host & microbe
- 2013 PloS one
- 2013 Nature reviews. Immunology
- 2013 Journal of virology
- 2013 The Journal of biological chemistry
- 2013 The Journal of biological chemistry
- 2013 PLoS biology
- 2012 Journal of virology
- 2012 Journal of virology
- 2012 Journal of virology
- 2012 PloS one
- 2012 PLoS pathogens
-
2011
Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses.Current opinion in microbiology
- 2011 Journal of virology
- 2011 Journal of virology
- 2011 Journal of virology
- 2011 PLoS pathogens
- 2011 Journal of neurochemistry
- 2010 Nature structural & molecular biology
- 2010 Journal of virology
- 2009 PLoS pathogens
- 2009 Journal of virology
- 2009 Methods in enzymology
- 2009 Journal of molecular biology
- 2009 Biochemistry
- 2009 Cell
- 2009 Cell host & microbe
- 2008 PLoS pathogens
- 2008 Journal of virology
- 2008 Proceedings of the National Academy of Sciences of the United States of America
- 2008 Proceedings of the National Academy of Sciences of the United States of America
- 2007 Nature
- 2007 Virology
- 2007 Antiviral therapy
- 2007 Virology
- 2007 Virology
- 2007 Virology
- 2006 Nature biotechnology
- 2006 The Journal of biological chemistry
- 2006 Advances in experimental medicine and biology
- 2006 The Journal of biological chemistry
- 2006 Advances in experimental medicine and biology
- 2006 Advances in experimental medicine and biology
- 2006 Advances in experimental medicine and biology
- 2006 The Journal of biological chemistry
-
2006
Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain.Journal of virology
- 2006 Journal of medical virology
- 2006 Journal of virology
- 2006 The Journal of biological chemistry
- 2006 Journal of immunology (Baltimore, Md. : 1950)
- 2005 Molecular microbiology
- 2005 Science (New York, N.Y.)
- 2005 Journal of virology
- 2005 The EMBO journal
- 2005 Molecular microbiology
- 2005 Current Alzheimer research
- 2005 Virology
- 2005 Journal of virology
- 2005 Virology
- 2005 Journal of virology
- 2005 The Journal of biological chemistry
- 2005 Journal of virology
- 2004 Proceedings of the National Academy of Sciences of the United States of America
- 2004 Journal of virology
- 2004 Biochemical and biophysical research communications
- 2004 Virology
- 2004 Proceedings of the National Academy of Sciences of the United States of America
- 2004 Journal of virology
- 2004 Cellular and molecular life sciences : CMLS
- 2004 The Journal of biological chemistry
- 2004 Journal of virology
- 2003 Nature
- 2003 Journal of neuroscience research
- 2003 The Journal of biological chemistry
- 2003 Cell
- 2002 The Journal of biological chemistry
- 2002 The Journal of biological chemistry
- 2002 Journal of virology
- 2002 The Journal of biological chemistry
- 2001 Journal of virology
- 2001 The Journal of experimental medicine
- 2001 The Journal of experimental medicine
- 2000 The Journal of biological chemistry
- 2000 Journal of virology
- 2000 Proceedings of the National Academy of Sciences of the United States of America
- 2000 Journal of virology
-
2000
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.Journal of virology
- 2000 Nature biotechnology
- 1999 Cell
- 1999 Journal of virology
- 1999 The Journal of biological chemistry
- 1998 Journal of virology
- 1998 Journal of immunology (Baltimore, Md. : 1950)
- 1998 Journal of virology
- 1998 Seminars in immunology
- 1998 Virology
- 1998 Journal of virology
- 1998 Journal of virology
- 1997 Journal of virology
- 1997 The Journal of experimental medicine
- 1997 Journal of virology
- 1997 The Journal of biological chemistry
- 1997 Nature
- 1997 Science (New York, N.Y.)
- 1996 Cell
- 1996 Nature
-
1997
Ph.D. in ImmunologyHarvard Medical School
-
1984
A.B. GovernmentHarvard College
Hyeryun Choe Ph.D.
- Mailing Address:
-
120 SCRIPPS WAY # B208
JUPITER FL 33458
Hyeryun Choe has done her graduate studies at Pennsylvania State University and received her Ph.D. degree from the Department of Biochemistry, Molelcular Biology, and Cell Biology in erythrocyte membrane lipid bilayer asymmetry in diseases such as sickle cell anemia. During her postdoctoral training at Beth Israel Hospital and Dana Farber Cancer Institute at Harvard Medical School, her research interests broadened to viruses and the mechanisms with which viruses enter cells and cause diseases. In the decade of 2000, as Assistant and Associate Professor at the Department of Pediatrics, Boston Children’s Hospital, Harvard Medical School, Dr. Choe discovered or co-discovered the HIV-1 coreceptors CCR3 and CCR5, the SARS-CoV receptor ACE2 when it emerged in the winter of 2002, and TFR1 as the receptor for all five South American hemorrhagic fever viruses. Of these, the identification of ACE2 as the receptor for SARS-CoV likely accelerated SARS-CoV-2 research because SARS-CoV-2 also uses ACE2 as its entry receptor. In the following decade after her relocation to the Scripps Research, Dr. Choe, as Associate Professor and Professor, studied the entry mechanisms of newly emerging viruses such as West Nile virus, Zika virus, and SARS-CoV-2. Her passion is to develop or contribute to developing effective vaccines or vaccine alternatives against dengue virus that infects hundreds of millions people and causes diseases in tens of millions a year.
Viruses enter cells through common underlying mechanisms. Parallel studies of the entry processes of various viruses can therefore highlight differences among them, as well as their similarities. The Choe laboratory studies a wide range of viruses to better understand their entry pathways and the mechanisms of pathogenesis of viral diseases. In doing so, we identified a number of viral receptor and host factors critical for viral infection and pathogenesis. These include: the HIV-1 coreceptor CCR5, and its post-translational modification tyrosine sulfation critical HIV-1 infection; the SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2) and the lysosomal enzyme cathepsin L as an essential target-cell factors for SARS-CoV infection; transferrin receptor 1 (TfR1) as the receptor for New World hemorrhagic fever arenaviruses, and an antibody that inhibits the infection of all five pathogenic New World arenaviruses. We also study how the TIM family of phosphatidylserine receptors promote infections of a wide range of enveloped viruses including filoviruses and flaviviruses such as West Nile, dengue and Zika viruses. More recently, we included adeno-associated virus (AAV), the preferred gene therapy vector, in our study with the goal of improving its transduction efficiency in specific target cells.
- 2022 Nature reviews. Molecular cell biology
- 2021 PLoS pathogens
- 2021 PLoS pathogens
- 2021 Science (New York, N.Y.)
- 2021 mBio
- 2021 ACS chemical biology
- 2021 Biochemical and biophysical research communications
- 2020 Immunity
- 2020 Molecular therapy. Methods & clinical development
- 2020 bioRxiv : the preprint server for biology
- 2020 bioRxiv : the preprint server for biology
- 2020 Journal of virology
- 2020 Nature communications
- 2020 bioRxiv : the preprint server for biology
- 2019 mBio
- 2019 mBio
- 2018 PLoS pathogens
- 2017 Proceedings of the National Academy of Sciences of the United States of America
- 2016 Scientific reports
- 2016 Antimicrobial agents and chemotherapy
- 2015 Proceedings of the National Academy of Sciences of the United States of America
- 2014 Journal of virology
- 2013 PLoS biology
- 2013 PLoS pathogens
- 2012 Journal of virology
- 2012 Journal of virology
- 2011 Journal of virology
- 2011 PLoS pathogens
-
2011
Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses.Current opinion in microbiology
- 2010 Nature structural & molecular biology
- 2009 Journal of virology
- 2009 PLoS pathogens
- 2009 Biochemistry
- 2009 Methods in enzymology
- 2008 Journal of virology
- 2008 Proceedings of the National Academy of Sciences of the United States of America
- 2008 Proceedings of the National Academy of Sciences of the United States of America
- 2007 Antiviral therapy
- 2007 Virology
- 2007 Nature
- 2006 Advances in experimental medicine and biology
- 2006 The Journal of biological chemistry
- 2006 Advances in experimental medicine and biology
- 2006 Nature biotechnology
- 2006 Journal of virology
- 2006 The Journal of biological chemistry
- 2006 The Journal of biological chemistry
- 2005 Molecular microbiology
- 2005 The EMBO journal
- 2005 Molecular microbiology
- 2004 The Journal of biological chemistry
- 2004 Journal of virology
- 2004 Virology
- 2004 Proceedings of the National Academy of Sciences of the United States of America
- 2004 Journal of virology
- 2004 Proceedings of the National Academy of Sciences of the United States of America
- 2003 Nature
- 2003 Cell
- 2002 The Journal of biological chemistry
- 2002 The Journal of biological chemistry
-
1984
Ph.D. in Microbiology, Biochemistry and Molecular BiologyPennsylvania State University
-
1980
Masters of Science in MicrobiologySeoul National University
-
1977
Bachelor's of ScienceSeoul National University
Laura Solt Ph.D.
- Mailing Address:
-
130 SCRIPPS WAY
JUPITER FL 33458
Laura A. Solt, Ph.D., is an Associate Professor in the Department of Immunology and Microbiology at Scripps Florida in Jupiter, Florida. She received her B.A. from Boston College and her Ph.D. in Immunology from the University of Pennsylvania. After completing her postdoctoral research at Scripps, she started her independent laboratory at Scripps Florida in 2013. Dr. Solt’s research is focused on understanding the biological roles of nuclear receptors in the immune system, with a specific focus on Th17 cells, and how their expression, function, and activity affects disease. Her lab uses a combination of molecular biology, genetic, and chemical biology approaches coupled with mouse models of autoimmunity and chronic inflammation to study the RORs, REV-ERBs, and NR2F6 either individually and/or cross-talk between the receptors. As ligand-regulated transcription factors, nuclear receptors function as excellent targets for the treatment of a variety of diseases. Therefore, we also work in close collaboration with medicinal chemists to design and develop small molecule ligands to these receptors to further probe their functions in vitro, in vivo, and to evaluate their therapeutic potential. Using these approaches, we described a negative regulatory role for the nuclear receptor REV-ERBa in Th17 cell development and autoimmunity. We also described the design and synthesis of newer, more potent synthetic REV-ERB modulators that target Th17 cells in vivo. Recently, we have extended our studies to better understand how heme, the REV-ERBs endogenous ligand, regulates REV-ERB activity in Th17 cells. Finally, we also described the design and synthesis of synthetic RORa modulators. We published a role for RORa in Th17 cells and the characterization of RORa-selective small molecules to target Th17 cells and treat Th17-mediated autoimmunity. Targeting the REV-ERBs or RORa demonstrate an alternative approach to the current design of RORgt modulators – of which many have entered clinical trials and failed for numerous reasons. Insight into the transcriptional regulation of nuclear receptors and their ligand(s) function is essential to comprehend the signaling pathways that govern Th17 cell homeostasis vs. pathogenicity as well as the rational design of therapeutics for specific disease indications.
-
Ruth L. Kirschstein National Research Service Awards2010-2013 · National Institutes of Health
The underlying theme of the research performed in the Solt laboratory is to understand the biologically relevant roles of nuclear receptors, a superfamily of ligand regulated transcription factors, in the immune system. Our lab uses a combination of molecular biology, genetic, and chemical biology approaches coupled with mouse models of autoimmunity and chronic inflammation to study how different nuclear receptors’ expression, function, and activity affects disease. As ligand-regulated transcription factors, nuclear receptors are excellent therapeutic targets for the treatment of a variety of diseases. Therefore, we also work in collaboration with medicinal chemists to develop small molecule ligands to these receptors to further probe their function in vitro and in vivo. Each receptor is unique and can have ligand- and/or tissue-specific effects. Thus, we aim to gain a better understanding of nuclear receptor activity in tissue and disease-specific contexts to determine their therapeutic potential and for more rational drug design.
- Autoimmune Disease
- Cancer Immunotherapy
- Immunometabolism
- Mucosal immunology
- Neuroimmunology
- 2022 Immunometabolism
- 2022 Immunometabolism
- 2022 SLAS discovery : advancing life sciences R & D
- 2022 Redox biology
- 2021 Nature
- 2021 Nature Communications
- 2021 Science advances
- 2021 Immunometabolism
- 2020 Nature communications
- 2020 Biochemical and biophysical research communications
- 2019 Nature
- 2019 Proceedings of the National Academy of Sciences of the United States of America
- 2019 Science immunology
- 2019 Medicinal chemistry (Shariqah (United Arab Emirates))
- 2018 PLoS biology
- 2018 Bioorganic & medicinal chemistry letters
- 2018 Cell reports
- 2018 Biochemical pharmacology
- 2018 PLOS ONE
- 2017 FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- 2016 PloS one
- 2016 ACS chemical biology
- 2016 European journal of immunology
- 2016 PloS one
- 2016 PloS one
- 2015 Cancer cell
- 2015 Proceedings of the National Academy of Sciences of the United States of America
- 2015 Biochemical and biophysical research communications
- 2015 Diabetes management (London, England)
- 2015 Endocrinology
- 2014 Nature communications
- 2014 The Journal of biological chemistry
- 2013 ACS chemical biology
- 2013 Pharmacological reviews
- 2013 Nature medicine
- 2012 Biochemistry
- 2012 Nature
- 2012 PloS one
- 2012 PloS one
- 2012 ACS chemical biology
- 2012 Trends in endocrinology and metabolism: TEM
- 2012 ACS chemical biology
- 2011 The Journal of biological chemistry
- 2011 ACS chemical biology
- 2011 Nature
- 2011 Future medicinal chemistry
- 2010 Current opinion in lipidology
- 2010 The Journal of biological chemistry
- 2010 Endocrinology
- 2010 The Journal of biological chemistry
- 2010 Molecular pharmacology
- 2007 The Journal of biological chemistry
-
2009-2013
Postdoctoral FellowThe Scripps Research Institute – Florida
-
2008
Ph.D. in ImmunologyUniversity of Pennsylvania
-
1998
Bachelor's of Science in PsychologyBoston College
Susana Valente Ph.D.
- Mailing Address:
-
Scripps Way
Jupiter FL 33458
-
Landenberger Foundation Award2010-2012 · Landenberger Foundation
-
Research Scholar Development Award (K22)2009-2011 · NIAID
-
PRAXIS XXI, Post-doctoral fellowship, 2007-082007-2008 · Portuguese Ministry of Education
-
Post-doctoral Fellowship2005-2007 · American Foundation for AIDS Research, AmfAR
-
PRAXIS XXI, Ph.D scholarship1998-2002 · Portuguese Ministry of Education
According to the latest statistics published by the UNAIDS/WHO in December 2007, 33.2 million people were living with the Human Immunodeficiency Virus (HIV). In 2007, 2.1 million people died as a result of the acquired Immunodeficiency Syndrome (AIDS). Although antiretroviral drugs have had a dramatically beneficial impact on HIV-infected individuals who have access to treatment, they have had a negligible impact on the global epidemic. Therapies for retroviral infections in humans now used in clinical practice have limitations in that they often only shorten the duration of disease symptoms or fail to completely eradicate the virus with viral replication and disease recurring after discontinuation of the drug therapy. Additionally, the emergence of HIV variants with drug-resistance is an ongoing clinical problem. Clearly having a larger repertoire of therapeutic agents would be beneficial for combating the HIV epidemic.
Retroviruses, due to their limited genome size and content, require the assistance of multiple host cellular proteins at each step in their elaborate replication cycle. Host cells, in response, have evolved many mechanisms for inhibiting viral replication. We have taken a general approach to identify the molecular interactions occurring within a cell that are critical for viral replication, or genes that have evolved in mammalian cells to block viral replication. The discovery of cellular factors involved in retroviral replication and an increased knowledge of their mode of action may lead to important antiviral approaches in clinical settings as one could block the modified use without affecting cell viability.
- 2022 Methods in molecular biology (Clifton, N.J.)
- 2022 SLAS discovery : advancing life sciences R & D
- 2021 Cell reports
- 2021 mBio
- 2021 The Journal of infectious diseases
- 2021 bioRxiv : the preprint server for biology
- 2020 Viruses
- 2020 Colloids and surfaces. B, Biointerfaces
- 2020 Viruses
- 2020 Journal of virology
- 2020 International journal of pharmaceutics
- 2019 mBio
- 2019 mBio
- 2019 Epigenetics & chromatin
- 2019 FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- 2017 Cell reports
- 2017 Methods in molecular biology (Clifton, N.J.)
- 2017 Current pharmaceutical design
- 2016 Angewandte Chemie (International ed. in English)
- 2016 Expert review of anti-infective therapy
- 2016 Antimicrobial agents and chemotherapy
- 2015 Current HIV research
- 2015 Current topics in microbiology and immunology
- 2015 Frontiers in microbiology
- 2015 mBio
- 2014 Journal of visualized experiments : JoVE
- 2012 Cell host & microbe
- 2012 Biology
- 2009 Molecular cell
- 2009 Proceedings of the National Academy of Sciences of the United States of America
- 2009 Methods in molecular biology (Clifton, N.J.)
- 2007 The EMBO journal
- 2006 Molecular cell
-
2002
Ph.D. Microbiology-VirologyUniversity of Paris Diderot (Paris VII)
-
1998
Master's of Science in BiotechnologyDe Montfort University
-
1997
Master's of Science in Maîtrise BiochemistryUniversity of Paris Diderot (Paris VII)
-
1996
Bachelor's of Science in Applied Chemistry and BiotechnologyNew University of Lisbon
Mauricio Martins Ph.D.
- Mailing Address:
-
120 SCRIPPS WAY
JUPITER FL 33458
-
Vaccine’s Young Investigator2016 · —
I am interested in developing practical immune interventions against globally relevant human pathogens. HIV is the current topic of my research. My group is using rhesus macaque models of HIV/AIDS to develop active and passive immunization strategies for preventing and treating HIV infection.
- 2021 Science translational medicine
- 2020 Journal of virology
Corinne Lasmézas Ph.D.
- Mailing Address:
-
120 SCRIPPS WAY
JUPITER FL 33458
Neurodegenerative diseases
Our laboratory focuses on the study of neurodegenerative diseases, especially those linked to protein misfolding (protein misfolding neurodegenerative diseases, or PMNDs). These diseases comprise Alzheimer’s, Parkinson’s, Huntington’s, prion diseases, fronto-temporal dementia, and amyotrophic lateral sclerosis. None of them are curable. They are all due to host proteins loosing their natural, functional conformation and adopting a new shape that renders them neurotoxic and prone to aggregation.
Prion diseases constitute the prototypic PMND. These rapidly fatal neurodegenerative diseases affect humans and animals and are caused by infectious aggregates of the prion protein PrP, called prions. In humans, prions cause Creutzfeldt-Jakob disease. In animals, the recent epidemic of bovine spongiform encephalopathy in the United Kingdom has caused major turmoil throughout Europe, and later, in other countries such as Japan, Canada and the United States, because the bovine prion disease is transmissible to humans causing variant Creutzfeldt-Jakob disease. The transmissibility of the latter by blood transfusion created a novel public health issue.
Alzheimer’s and Parkinson’s diseases affect 5.8 and 1 Million people in the USA, respectively. Their incidence has steadily increased with an aging population, having a major impact on public health, society and the economy. Alzheimer’s disease is the 6th leading cause of death in developed countries. Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) is an orphan disease causing a progressive muscle weakness and paralysis, affecting an estimated 30,000 people in the USA.
In recent years, it has been discovered that aggregates of amyloidogenic proteins such as Ab, tau, a-synuclein or SOD-1 involved in Alzheimer’s, Parkinson diseases and amyotrophic lateral sclerosis, respectively, spread from cell to cell in culture and in the living organism similarly to PrP aggregates, showing “prion-like” behavior. There are other features common to these toxic proteins and the way they injure neurons (e.g. toxicity of low molecular weight aggregates, impairment of protein degradation mechanisms such as autophagy, mitochondrial distress).
Our aim is the development of novel, disease-modifying therapeutic approaches for protein misfolding neurodegenerative diseases. We think that this aim will be best achieved by intervention strategies based on targeting toxic protein aggregates, and blocking the neurodegenerative process to achieve neuroprotection. We are pursuing these goals by studying the underlying biology, defining therapeutic targets, identifying active molecules by high-throughput screening and developing lead compounds. The latter two tasks are performed in collaboration with our lead identification and chemist colleagues on campus.
- 2019 Neurobiology of disease
- 2018 Handbook of clinical neurology
- 2018 Proceedings of the National Academy of Sciences of the United States of America
- 2017 Food safety (Tokyo, Japan)
- 2015 Brain : a journal of neurology
- 2015 The EMBO journal
- 2013 Proceedings of the National Academy of Sciences of the United States of America
- 2012 Proceedings of the National Academy of Sciences of the United States of America
- 2012 Expert review of proteomics
- 2012 Journal of virology
- 2009 Neuroscience
- 2009 PloS one
- 2008 PloS one
- 2007 Prion
- 2007 PLoS pathogens
- 2006 Neuroreport
- 2006 The Lancet. Neurology
- 2005 Journal of virology
- 2005 Lancet (London, England)
- 2004 Transgenic research
- 2004 Lancet (London, England)
- 2004 Lancet (London, England)
- 2003 The Journal of general virology
- 2003 Biological chemistry
- 2003 Journal of virology
- 2003 British medical bulletin
- 2003 EMBO reports
- 2003 Revue scientifique et technique (International Office of Epizootics)
- 2001 Proceedings of the National Academy of Sciences of the United States of America
- 2001 Veterinary journal (London, England : 1997)
- 2001 The EMBO journal
-
2001
The 37-kDa/67-kDa laminin receptor acts as the cell-surface receptor for the cellular prion protein.The EMBO journal
- 2000 Neurobiology of disease
- 2000 The Journal of pathology
- 1999 Neuroreport
- 1999 Biochemical and biophysical research communications
- 1999 Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
- 1999 Journal of neuroscience research
- 1998 Cell and tissue research
- 1998 The Journal of biological chemistry
- 1997 Science (New York, N.Y.)
- 1997 Nature medicine
- 1997 Journal of virology
- 1997 Lancet (London, England)
- 1996 Bulletin de l'Academie nationale de medecine
- 1996 Nature
- 1996 Research in virology
- 1996 Journal of virology
- 1996 The Journal of general virology
- 1994 The Journal of general virology
- 1994 Lancet (London, England)
- 1993 Biochemical and biophysical research communications
-
1995
Ph.D. in NeurosciencesPierre and Marie Curie University
-
1993
Doctor of Veterinary MedicineUniversity of Toulouse, Toulouse National Veterinary School
-
1992
Master's of Science in NeurosciencesPierre and Marie Curie University
-
1990
Diploma in Aeronautic and Space MedicineUniversity of Toulouse, University of Medicine
Christoph Rader Ph.D.
- Mailing Address:
-
130 SCRIPPS WAY
JUPITER FL 33458
Next-generation antibodies for cancer therapy
- Antibodies
- Biochemistry
- Cancer Immunology and Immunotherapy
- Chemical biology
- 2022 Organic letters
- 2022 Bioconjugate Chemistry
- 2022 Leukemia research
- 2021 Molecular therapy oncolytics
- 2021 Blood advances
- 2021 Leukemia
- 2021 PLOS Pathogens
- 2021 Immuno-oncology technology
- 2021 Cancer Cell
- 2021 Scientific reports
- 2021 Antibody Therapeutics
- 2021 Blood
- 2021 Oncogene
- 2021 Biochemistry
- 2021 Journal of Industrial Microbiology and Biotechnology
- 2020 Biomolecules
- 2020 Nature Communications
- 2020 Bioorganic & medicinal chemistry
- 2020 Angewandte Chemie
- 2020 Nucleic Acids Research
- 2020 Angewandte Chemie International Edition
- 2020 Journal of Medicinal Chemistry
- 2020 Current Opinion in Biotechnology
- 2020 Journal of Biological Chemistry
- 2019 Haematologica
- 2019 Bioconjugate Chemistry
- 2019 Cell chemical biology
- 2019 Blood
- 2019 Developmental and comparative immunology
- 2019 Cancer cell
- 2019 Methods in molecular biology (Clifton, N.J.)
- 2019 Antibody therapeutics
-
2019
Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.Frontiers in immunology
- 2019 Molecular therapy : the journal of the American Society of Gene Therapy
- 2019 Methods (San Diego, Calif.)
- 2018 Cancer immunology research
- 2018 Proceedings of the National Academy of Sciences of the United States of America
- 2018 Organic letters
- 2018 Journal of molecular biology
- 2018 Blood
- 2018 Advances in cell and gene therapy
- 2017 Experimental & molecular medicine
- 2017 Organic letters
- 2017 Nature communications
- 2017 Journal of molecular biology
- 2017 Cell chemical biology
- 2017 Methods in molecular biology (Clifton, N.J.)
- 2017 The Journal of biological chemistry
- 2016 The Journal of biological chemistry
- 2016 Bioconjugate chemistry
- 2016 mBio
- 2016 Bioorganic & medicinal chemistry
- 2016 The Journal of biological chemistry
- 2016 Organic & biomolecular chemistry
- 2016 Bioconjugate chemistry
- 2015 Bioconjugate chemistry
- 2015 Leukemia
- 2015 Cancer immunology research
- 2015 Cancer immunology research
- 2015 PloS one
- 2015 Biochemistry
- 2015 Journal of natural products
- 2015 Experimental hematology
- 2015 Nature
- 2014 Methods (San Diego, Calif.)
- 2014 Trends in biotechnology
- 2014 Cancer research
- 2014 Bioconjugate chemistry
- 2014 Chemistry & biology
- 2014 PloS one
- 2013 Current protocols in cell biology
- 2013 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2012 Bioconjugate chemistry
- 2012 The Journal of biological chemistry
- 2012 Methods in molecular biology (Clifton, N.J.)
- 2012 PloS one
- 2012 Methods in molecular biology (Clifton, N.J.)
- 2012 mAbs
- 2012 Methods in molecular biology (Clifton, N.J.)
- 2011 Cold Spring Harbor protocols
- 2011 Cold Spring Harbor protocols
- 2011 Blood
- 2011 PloS one
- 2011 International journal of cancer
- 2011 Blood
- 2011 Blood
- 2010 Journal of molecular biology
- 2010 Proceedings of the National Academy of Sciences of the United States of America
- 2010 Blood
- 2010 mAbs
- 2010 Blood
- 2010 Cytometry. Part B, Clinical cytometry
- 2009 Biochemistry
- 2009 Current protocols in protein science
- 2009 The Journal of neuroscience : the official journal of the Society for Neuroscience
- 2009 Current protocols in protein science
- 2009 Proceedings of the National Academy of Sciences of the United States of America
- 2009 Methods in molecular biology (Clifton, N.J.)
- 2009 Blood
- 2008 Proceedings of the National Academy of Sciences of the United States of America
- 2008 Bioorganic & medicinal chemistry letters
- 2008 Journal of molecular biology
- 2008 Restorative neurology and neuroscience
- 2008 Clinical cancer research : an official journal of the American Association for Cancer Research
- 2007 Proceedings of the National Academy of Sciences of the United States of America
- 2007 Journal of immunological methods
- 2006 International journal of cancer
- 2005 Bioscience, biotechnology, and biochemistry
- 2005 Proceedings of the National Academy of Sciences of the United States of America
- 2005 Cancer research
- 2005 The Journal of neuroscience : the official journal of the Society for Neuroscience
- 2004 Proceedings of the National Academy of Sciences of the United States of America
- 2004 Bioorganic & medicinal chemistry
- 2004 Journal of immunological methods
- 2004 Chemistry (Weinheim an der Bergstrasse, Germany)
- 2004 Journal of immunological methods
- 2004 Journal of medicinal chemistry
- 2004 FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- 2003 Angewandte Chemie (International ed. in English)
- 2003 Journal of molecular biology
- 2003 Proceedings of the National Academy of Sciences of the United States of America
- 2003 The Journal of biological chemistry
- 2003 Journal of molecular biology
- 2002 FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- 2002 The Journal of biological chemistry
- 2001 Current protocols in cell biology
- 2001 Drug discovery today
- 2001 Proceedings of the National Academy of Sciences of the United States of America
- 2001 Molecular and cellular neurosciences
- 2000 Proceedings of the National Academy of Sciences of the United States of America
-
2000
The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies.The Journal of biological chemistry
- 2000 Journal of immunological methods
- 2000 Advances in protein chemistry
- 2000 Chemistry (Weinheim an der Bergstrasse, Germany)
- 2000 The Journal of cell biology
- 2000 The Journal of biological chemistry
- 1999 Proceedings of the National Academy of Sciences of the United States of America
- 1998 Proceedings of the National Academy of Sciences of the United States of America
- 1998 Progress in brain research
- 1998 The Journal of cell biology
- 1997 Current opinion in biotechnology
- 1996 The Journal of cell biology
- 1996 The EMBO journal
- 1995 European journal of biochemistry
- 1993 European journal of biochemistry
- 1993 European journal of biochemistry
- 1992 European journal of biochemistry
-
1995
Ph.D. in BiochemistryUniversity of Zurich (Switzerland)
-
1991
Master's of Science in BiochemistryUniversity of Zurich (Switzerland)
-
1988
Bachelor's of Science in BiochemistryUniversity of Bayreuth (Germany)
Guocai Zhong Ph.D.
- Mailing Address:
-
Scripps Way
Jupiter FL 33458